Success Metrics

Completion Rate

0%(0/1)

Active Trials

0(0%)

Terminated

1(33%)

Phase Distribution

Ph phase_2

33%

Ph phase_4

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

1(33.3%)

Phase 4Post-market surveillance

2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Terminated(2)

Detailed Status

Terminated1

Enrolling by invitation1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 4

Trials by Phase

Phase 21 (33.3%)

Phase 42 (66.7%)

Trials by Status

terminated133%

enrolling_by_invitation133%

withdrawn133%

Recent Activity

0 active trials

Showing 3 of 3

enrolling_by_invitationphase_4

Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

NCT07298993

terminatedphase_2

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

NCT02927366

withdrawnphase_4

Antibiotics in Chronic Obstructive Pulmonary Disease (COPD)

NCT00952861

Clinical Trials (3)

Showing 3 of 3 trials

NCT07298993Phase 4

Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

Enrolling By Invitation

NCT02927366Phase 2

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

Terminated

NCT00952861Phase 4

Antibiotics in Chronic Obstructive Pulmonary Disease (COPD)

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3